UCL Study: Decipher Test Could Show Which High-Risk Prostate Cancer Patients Need Abiraterone

3.0 · 5d ago · WORLD

The Facts

  • Researchers at University College London (UCL) analyzed the Decipher tissue-based molecular test to determine which men with high-risk prostate cancer are most likely to benefit from intensified treatment. Fox News only
  • The analysis used Decipher scores from more than 27,000 patients in real-world data and 401 men with non-metastatic prostate cancer who took part in the STAMPEDE abiraterone trial. Fox News only
  • The STAMPEDE trial found that adding abiraterone to standard treatment could cut the risk of death in half for men with high-risk, localized prostate cancer. Fox News only
  • Higher Decipher scores predicted worse outcomes and greater likelihood of spread; low scores suggested more intensive treatment may be unnecessary. Fox News only
  • The findings were presented at the ESMO Congress in Madrid, held Oct. 23-27. Fox News gives the year as 2026. Fox News only
Dive deeper · 2 more factsShow less
  • Lead researcher Dr. Sarah Howlett of the UCL Cancer Institute said further validation in other datasets is needed before the test is used routinely for these decisions. Fox News only
  • Decipher is made by Veracyte, whose urology medical director Elai Davicioni said the evidence gives physicians stronger reason to use the test. Fox News only

Context

UCL researchers examined whether the Decipher genomic test can identify which men with high-risk, localized prostate cancer benefit most from adding the hormone therapy abiraterone. The same pattern appeared in both a large real-world dataset and a randomized trial cohort.

The lead researcher said further validation is needed before routine use. The test's maker, Veracyte, has a commercial interest in the findings. Fox News medical analyst Dr. Marc Siegel, not involved in the study, called the approach a move toward personalized treatment.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 0.

3 Business Analyst This is a conference-presented medical research finding on a biomarker test with limited market or economic impact, and the lead researcher notes further validation is needed before routine use, so it is a niche clinical development rather than market-moving news.
3 News Editor This is a niche medical research presentation at a conference, with a finding that still needs validation before routine clinical use, so its concrete impact on patients is limited for now.
3 Informed Citizen This is a conference-presented research analysis of a biomarker that the lead researcher says still needs validation before routine use, so it affects few people immediately and has limited near-term impact.

Source

← All stories